Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mary E. Valiant is active.

Publication


Featured researches published by Mary E. Valiant.


Chemotherapy | 1984

An Experimental Model for Evaluation of Antifungal Agents in a Trichophyton mentagrophytes Infection of Guinea Pigs

Mary E. Valiant; Bettina M. Frost

A Trichophyton mentagrophytes infection of guinea pigs induced by an occlusive procedure is described. The method of evaluation permits comparison of efficacy of antifungal agents which are not tested simultaneously. Activity was demonstrated following topical application of clotrimazole, miconazole, tolnaftate or griseofulvin and oral administration of griseofulvin. Oral ketoconazole had little effect in this dermatophyte model.


Experimental Biology and Medicine | 1957

Binding of Novobiocin with Plasma Proteins

David M. Tennent; Richard C. Mason; Gunther W. Kuron; Mary E. Valiant; Morris Solotorovsky

Summary 1. Fraction studies with plasma from a dog treated with novobiocin showed that novobiocin is extensively bound to plasma albumin. 2. In vitro experiments with crystalline bovine albumin showed that the binding is a reversible process.


Chemotherapy | 1976

In vitro and in vivo Activity of 3-(1-Methyl 1-5-Nitro-2 Imidazolylmethylideneamino)-2-OxazoIidinone against Pasteurella

Bettina M. Frost; Mary E. Valiant; Eugene L. Dulaney

Furazolidone was more active than 3-(1-methyl)-5-nitro-2-imidazolyl-methylideneamino)-2-oxazolidinone (MABN) against a series of 34 isolates of Pasteurella and 11 of Yersinia (forme


Applied and Environmental Microbiology | 1983

GELRITE as an Agar Substitute in Bacteriological Media.

Daniel L. Shungu; Mary E. Valiant; Vicki Tutlane; Ellen Weinberg; Barbara Weissberger; Larry Koupal; Hans H. Gadebusch; Edward O. Stapley


The Journal of Antibiotics | 1976

ANTIBACTERIAL ACTIVITY OF EFROTOMYCIN

Bettina M. Frost; Mary E. Valiant; Barbara Weissberger; Eugene L. Dulaney


Archive | 1988

Method of controlling mycotic infections and compositions therefor

Hans H. Gadebusch; Mary E. Valiant


The Journal of Antibiotics | 1989

L-658,310, a new injectable cephalosporin. I. In vitro antibacterial properties.

Barbara Weissberger; George K. Abruzzo; Robert A. Fromtling; Charles Gill; Suzanne Ponticas; Mary E. Valiant; Daniel L. Shungu; Hans H. Gadebusch


The Journal of Antibiotics | 1979

ANTIBACTERIAL ACTIVITY OF HENEICOMYCIN

Bettina M. Frost; Mary E. Valiant; Eugene L. Dulaney


Antibiotics and Chemotherapy | 1959

Laboratory Studies on the Antibacterial Activity Of Kanamycin.

A. Kathrine Miller; Mary E. Valiant; Bettina M. Frost


The Journal of Antibiotics | 1989

L-658,310, a new injectable cephalosporin. II. In vitro and in vivo interactions between L-658,310 and various aminoglycosides or ciprofloxacin versus clinical isolates of Pseudomonas aeruginosa.

Mary E. Valiant; Evemarie C. Gilfillan; Hans H. Gadebusch; Barbara A. Pelak

Researchain Logo
Decentralizing Knowledge